25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 25 of 25 clinical reviews.
A clinical review of CJC-1295 modified GRF and its potential impact on cognitive function, including GH/IGF-1 signaling pathways, trial data, dosing considerations, and what patients should realistically expect.
A clinical deep-dive into how CJC-1295 (modified GRF 1-29) influences growth hormone pulsatility, lipolysis, resting metabolic rate, and body composition, with primary-literature citations and dosing context for telehealth prescribers.
A clinician-level review of how CJC-1295 modified GRF affects appetite, hunger hormones, and food cravings, with primary-literature citations and practical dosing context.
A physician-level review of CJC-1295 modified GRF use in patients with autoimmune conditions, covering IGF-1 immunomodulation, disease-specific risks, monitoring protocols, and current evidence gaps.
A clinician-level review of how CJC-1295 modified GRF affects bone mineral density, osteoblast activity, and fracture risk, with primary-literature citations and dosing context.
A physician-level review of CJC-1295 (modified GRF 1-29) and cancer risk, covering IGF-1 biology, preclinical data, the Teichman trial, and how clinicians should weigh these signals before prescribing.
A clinician-level review of CJC-1295 (modified GRF) cardiovascular effects, covering cardiac output, blood pressure, lipid remodeling, IGF-1 signaling, and long-term risk framing based on primary literature.
A physician-reviewed comparison of compounded CJC-1295 (modified GRF 1-29) versus branded growth hormone secretagogue formulations, covering pharmacokinetics, dosing, regulatory status, purity data, and clinical evidence from Teichman et al. And related trials.
A rigorous GRADE-level review of CJC-1295 (modified GRF) clinical evidence, covering pharmacology, trial data from Teichman et al. 2006, and what the research does and does not support for GH secretagogue therapy.
A physician-reviewed deep dive into how CJC-1295 (modified GRF) affects hair growth, skin thickness, collagen synthesis, and sebum production, with primary-literature citations and dosing context.
A physician-level review of how CJC-1295 (modified GRF) affects liver enzymes, IGF-1 hepatic signaling, and clinical safety markers, with primary-literature citations.
A clinician-level review of how CJC-1295 (modified GRF) affects mood, cognition, sleep quality, and mental health outcomes, with primary-literature citations and dosing context.
A physician-reviewed analysis of CJC-1295 microdosing protocols, covering the pharmacokinetics, available clinical data, dosing frameworks used in 503A compounding practice, and what board-certified endocrinologists say about evidence gaps.
A physician-reviewed breakdown of CJC-1295 modified GRF for muscle preservation, covering mechanism, dosing protocols, clinical evidence, and how to combine it safely with resistance training and nutrition.
MD/PharmD-level guide to diagnosing and correcting CJC-1295 plateaus and non-response: receptor downregulation, dosing errors, injection technique, IGF-1 monitoring, and evidence-based fixes.
A physician-reviewed guide to CJC-1295 (modified GRF) use after bariatric surgery, covering pharmacology, GH/IGF-1 dynamics, dosing considerations, safety, and the evidence base including Teichman et al. 2006.
Evidence-based guidance on how long to hold CJC-1295 (modified GRF) before surgery, including GH physiology, anesthesia interactions, and restart timing from HealthRX physicians.
Does stopping CJC-1295 cause rebound effects? A physician-reviewed guide covering GH axis suppression, IGF-1 normalization timelines, and what the clinical literature says about discontinuation.
A clinical review of CJC-1295 modified GRF and its effects on renal function, covering GH/IGF-1 physiology, animal data, human pharmacokinetics, known risks, and prescribing considerations for patients with kidney disease.
Evidence-based protocol for restarting CJC-1295 modified GRF after acute illness. Covers timing, dose titration, IGF-1 monitoring, and contraindications reviewed by the HealthRX medical team.
A physician-reviewed guide to CJC-1295 (modified GRF) seasonal use considerations, including dosing adjustments, GH pulsatility, IGF-1 monitoring, and timing protocols across winter and summer cycles.
A clinical deep-dive into how CJC-1295 (modified GRF) affects libido, erectile function, and hormonal pathways related to sexual health, with primary-literature citations and dosing context.
A physician-reviewed, primary-literature analysis of how CJC-1295 (modified GRF) affects slow-wave sleep, GH pulse timing, and overnight IGF-1 secretion, with dosing context and clinical considerations.
Board-reviewed protocols for adjusting CJC-1295 (modified GRF) dosing schedules across time zones, including jet-lag pharmacology, storage during travel, and dose-timing decision frameworks.
A physician-reviewed, week-by-week guide to CJC-1295 (modified GRF 1-29) covering sleep, body composition, IGF-1 kinetics, and dosing protocols across the first four weeks.